Evidence map›Paper›PMID 31396030›Full record

ReviewFrontiers in neuroscience2019

Re-thinking the Etiological Framework of Neurodegeneration.

Ximena Castillo, Susana Castro-Obregón, Benjamin Gutiérrez-Becker, Gabriel Gutiérrez-Ospina, Nikolaos Karalis, Ahmed A Khalil, José Sócrates Lopez-Noguerola, Liliana Lozano Rodríguez, Eduardo Martínez-Martínez, Claudia Perez-Cruz and 9 more

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ximena CastilloInstituto de Neurobiología, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Susana Castro-ObregónInstituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Benjamin Gutiérrez-BeckerArtificial Intelligence in Medical Imaging KJP, Ludwig Maximilian University of Munich, Munich, Germany.
Gabriel Gutiérrez-OspinaLaboratorio de Biología de Sistemas, Departamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas y Coordinación de Psicobiología y Neurociencias, Facultad de Psicología, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Nikolaos KaralisFriedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Ahmed A KhalilCenter for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
José Sócrates Lopez-NoguerolaSchool of Health Sciences, Department of Gerontology, Autonomous University of Hidalgo State, Pachuca, Mexico.
Liliana Lozano RodríguezDepartamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Eduardo Martínez-MartínezCell Communication & Extracellular Vesicles Laboratory, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Claudia Perez-CruzNational Polytechnic Institute, Center of Research in Advanced Studies, Mexico City, Mexico.
Judith Pérez-VelázquezDepartamento de Matemáticas y Mecánica, Instituto de Investigaciones en Matemáticas Aplicadas y Sistemas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Ana Luisa PiñaDepartment of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Karla RubioLung Cancer Epigenetics, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Héctor Pedro Salazar GarcíaLeibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.
Tauqeerunnisa SyedaNational Polytechnic Institute, Center of Research in Advanced Studies, Mexico City, Mexico.
America Vanoye-CarloLaboratorio de Neurociencias, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City, Mexico.
Arno VillringerCenter for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Katarzyna WinekThe Shimon Peres Postdoctoral Fellow at the Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Marietta ZilleInstitute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases are among the leading causes of disability and death worldwide. The disease-related socioeconomic burden is expected to increase with the steadily increasing life expectancy. In spite of decades of clinical and basic research, most strategies designed to manage degenerative brain diseases are palliative. This is not surprising as neurodegeneration progresses "silently" for decades before symptoms are noticed. Importantly, conceptual models with heuristic value used to study neurodegeneration have been constructed retrospectively, based on signs and symptoms already present in affected patients; a circumstance that may confound causes and consequences. Hence, innovative, paradigm-shifting views of the etiology of these diseases are necessary to enable their timely prevention and treatment. Here, we outline four alternative views, not mutually exclusive, on different etiological paths toward neurodegeneration. First, we propose neurodegeneration as being a secondary outcome of a primary cardiovascular cause with vascular pathology disrupting the vital homeostatic interactions between the vasculature and the brain, resulting in cognitive impairment, dementia, and cerebrovascular events such as stroke. Second, we suggest that the persistence of senescent cells in neuronal circuits may favor, together with systemic metabolic diseases, neurodegeneration to occur. Third, we argue that neurodegeneration may start in response to altered body and brain trophic interactions established via the hardwire that connects peripheral targets with central neuronal structures or by means of extracellular vesicle (EV)-mediated communication. Lastly, we elaborate on how lifespan body dysbiosis may be linked to the origin of neurodegeneration. We highlight the existence of bacterial products that modulate the gut-brain axis causing neuroinflammation and neuronal dysfunction. As a concluding section, we end by recommending research avenues to investigate these etiological paths in the future. We think that this requires an integrated, interdisciplinary conceptual research approach based on the investigation of the multimodal aspects of physiology and pathophysiology. It involves utilizing proper conceptual models, experimental animal units, and identifying currently unused opportunities derived from human data. Overall, the proposed etiological paths and experimental recommendations will be important guidelines for future cross-discipline research to overcome the translational roadblock and to develop causative treatments for neurodegenerative diseases.

Indexed as

body–brain trophismdysbiosislifespansenescencevascular pathology

Identifiers

PMID31396030
PMCPMC6667555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.